AMGN
Amgen Inc.
Price Chart
Latest Quote
$349.58
+3.98 (+1.15%)
Current Price
| Previous Close | $345.60 |
| Open | $348.68 |
| Day High | $356.50 |
| Day Low | $347.66 |
| Volume | 3,449,414 |
Stock Information
| Quarterly Dividend / Yield | $10.08 / 2.92% |
| Shares Outstanding | 539.71M |
| Quarterly Dividend Yield | 2.92% |
| Quarterly Dividend | $10.08 |
| Total Debt | $57.32B |
| Cash Equivalents | $12.04B |
| Revenue | $37.22B |
| Net Income | $7.80B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $188.67B |
| P/E Ratio | 24.31 |
| EPS (TTM) | $14.38 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $231.81B |
| Sales | $37.22B |
| Income | $7.80B |
| Book/sh | $17.03 |
| Cash/sh | $22.30 |
| Employees | 32K |
Financial Ratios
| Quick Ratio | 0.85 |
| Current Ratio | 1.26 |
| Debt/Eq | 623.75 |
| EPS Growth TTM | 5.10% |
Returns & Margins
| ROA | 8.35% |
| ROE | 101.32% |
| Gross Margin | 71.44% |
| Operating Margin | 33.80% |
| Profit Margin | 20.96% |
Ownership
| Insider Ownership | 0.22% |
| Institutional Ownership | 85.46% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 14.89 |
| PEG | 2.17 |
| P/S | 5.07 |
| P/B | 20.53 |
Analyst Data
| Recommendation | buy |
| Target Price | $352.23 |
Technical Indicators
| SMA20 | $334.18 |
| SMA50 | $338.89 |
| SMA200 | $325.06 |
| RSI | 72.86 |
| ATR | 7.9486 |
| Shares Float | 538.23M |
| Short Float | 2.28% |
| Short Ratio | 4.60 |
| Volatility | 0.42 |
| Rel Volume | 1.41 |
Performance History
| Week | +3.80% |
| Month | +6.38% |
| Quarter | -4.68% |
| 6 Months | +2.68% |
| YTD | +8.25% |
| Year | +25.46% |
| 3 Years | +73.72% |
| 5 Years | +71.97% |
| 10 Years | +194.04% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $349.58 | 3,449,414 |
| 2026-06-04 | $345.60 | 2,907,100 |
| 2026-06-03 | $338.22 | 2,289,300 |
| 2026-06-02 | $328.26 | 1,558,800 |
| 2026-06-01 | $329.13 | 2,120,500 |
| 2026-05-29 | $336.79 | 2,953,800 |
| 2026-05-28 | $336.48 | 2,159,000 |
| 2026-05-27 | $336.06 | 1,929,500 |
| 2026-05-26 | $335.94 | 1,860,200 |
| 2026-05-22 | $339.30 | 1,566,200 |
| 2026-05-21 | $337.42 | 2,001,000 |
| 2026-05-20 | $331.57 | 4,074,400 |
| 2026-05-19 | $330.75 | 3,040,400 |
| 2026-05-18 | $324.39 | 2,030,100 |
| 2026-05-15 | $326.31 | 3,447,700 |
| 2026-05-14 | $333.71 | 2,041,600 |
| 2026-05-13 | $333.93 | 2,183,800 |
| 2026-05-12 | $333.77 | 3,119,100 |
| 2026-05-11 | $327.12 | 1,918,800 |
| 2026-05-08 | $329.21 | 2,443,200 |
| 2026-05-07 | $326.62 | 3,296,900 |
| 2026-05-06 | $328.63 | 2,874,400 |
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
đ° Latest News
Is Oncology Approval And Autoimmune Data Momentum Altering The Investment Case For Amgen (AMGN)?
Simply Wall St. âĸ 2026-06-05T14:18:34Z
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
Zacks âĸ 2026-06-05T13:07:00Z
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
MarketBeat âĸ 2026-06-05T05:02:28Z
75% Upside For LLY Stock?
Trefis âĸ 2026-06-04T20:23:28Z
Quantinuum Shares Pare Gains to Close Little Changed After IPO
Bloomberg âĸ 2026-06-04T20:21:23ZAlkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-04T15:30:06Z
Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split
Barchart âĸ 2026-06-04T13:35:02Z
Dear Future Quantinuum Stock Investors, Mark Your Calendars for June 3
Barchart âĸ 2026-06-02T15:41:39Z
ASCO 2026: Mixed SCLC result for Legendâs LB2102, Novartis expedites manufacture
Pharmaceutical Technology âĸ 2026-06-02T15:28:06Z
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication
Zacks âĸ 2026-06-02T15:15:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $12,037,000,000 | $12,858,000,000 | $8,451,000,000 | $6,406,000,000 |
| Cost Of Revenue | $12,037,000,000 | $12,858,000,000 | $8,451,000,000 | $6,406,000,000 |
| Total Revenue | $36,751,000,000 | $33,424,000,000 | $28,190,000,000 | $26,323,000,000 |
| Operating Revenue | $35,148,000,000 | $32,026,000,000 | $26,910,000,000 | $24,801,000,000 |
| Expenses | ||||
| Interest Expense | $2,755,000,000 | $3,155,000,000 | $2,875,000,000 | $1,406,000,000 |
| Total Expenses | $27,671,000,000 | $26,166,000,000 | $20,293,000,000 | $16,757,000,000 |
| Other Income Expense | $2,651,000,000 | $506,000,000 | $2,833,000,000 | $-814,000,000 |
| Other Non Operating Income Expenses | $2,651,000,000 | $506,000,000 | $2,833,000,000 | $-814,000,000 |
| Net Non Operating Interest Income Expense | $-2,755,000,000 | $-3,155,000,000 | $-2,875,000,000 | $-1,406,000,000 |
| Interest Expense Non Operating | $2,755,000,000 | $3,155,000,000 | $2,875,000,000 | $1,406,000,000 |
| Operating Expense | $15,634,000,000 | $13,308,000,000 | $11,842,000,000 | $10,351,000,000 |
| Other Operating Expenses | $1,312,000,000 | $248,000,000 | $879,000,000 | $503,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $7,711,000,000 | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 |
| Net Interest Income | $-2,755,000,000 | $-3,155,000,000 | $-2,875,000,000 | $-1,406,000,000 |
| Normalized Income | $7,711,000,000 | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 |
| Net Income From Continuing And Discontinued Operation | $7,711,000,000 | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 |
| Total Operating Income As Reported | $9,080,000,000 | $7,258,000,000 | $7,897,000,000 | $9,566,000,000 |
| Net Income Common Stockholders | $7,711,000,000 | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 |
| Net Income | $7,711,000,000 | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 |
| Net Income Including Noncontrolling Interests | $7,711,000,000 | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 |
| Net Income Continuous Operations | $7,711,000,000 | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 |
| Pretax Income | $8,976,000,000 | $4,609,000,000 | $7,855,000,000 | $7,346,000,000 |
| Operating Income | $9,080,000,000 | $7,258,000,000 | $7,897,000,000 | $9,566,000,000 |
| Gross Profit | $24,714,000,000 | $20,566,000,000 | $19,739,000,000 | $19,917,000,000 |
| Special Income Charges | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $14.23 | $7.56 | $12.49 | $12.11 |
| Basic EPS | $14.33 | $7.62 | $12.56 | $12.18 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $16,898,000,000 | $13,356,000,000 | $14,801,000,000 | $12,169,000,000 |
| Reconciled Depreciation | $5,167,000,000 | $5,592,000,000 | $4,071,000,000 | $3,417,000,000 |
| EBITDA (Bullshit earnings) | $16,898,000,000 | $13,356,000,000 | $14,801,000,000 | $12,169,000,000 |
| EBIT | $11,731,000,000 | $7,764,000,000 | $10,730,000,000 | $8,752,000,000 |
| Diluted Average Shares | $542,000,000 | $541,000,000 | $538,000,000 | $541,000,000 |
| Basic Average Shares | $538,000,000 | $537,000,000 | $535,000,000 | $538,000,000 |
| Diluted NI Availto Com Stockholders | $7,711,000,000 | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 |
| Tax Provision | $1,265,000,000 | $519,000,000 | $1,138,000,000 | $794,000,000 |
| Research And Development | $7,272,000,000 | $5,964,000,000 | $4,784,000,000 | $4,434,000,000 |
| Selling General And Administration | $7,050,000,000 | $7,096,000,000 | $6,179,000,000 | $5,414,000,000 |
| Total Unusual Items | - | - | $0 | $0 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-05-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-32,298,000,000 | $-40,459,000,000 | $-45,038,000,000 | $-27,948,000,000 |
| Total Assets | $90,586,000,000 | $91,839,000,000 | $97,154,000,000 | $65,121,000,000 |
| Total Non Current Assets | $61,529,000,000 | $62,809,000,000 | $66,822,000,000 | $42,935,000,000 |
| Other Non Current Assets | $12,660,000,000 | $9,930,000,000 | $9,611,000,000 | $5,899,000,000 |
| Goodwill And Other Intangible Assets | $40,956,000,000 | $46,336,000,000 | $51,270,000,000 | $31,609,000,000 |
| Other Intangible Assets | $22,276,000,000 | $27,699,000,000 | $32,641,000,000 | $16,080,000,000 |
| Current Assets | $29,057,000,000 | $29,030,000,000 | $30,332,000,000 | $22,186,000,000 |
| Other Current Assets | $1,188,000,000 | $1,138,000,000 | $281,000,000 | $355,000,000 |
| Prepaid Assets | $2,945,000,000 | $2,139,000,000 | $1,647,000,000 | $1,204,000,000 |
| Inventory | $6,225,000,000 | $6,998,000,000 | $9,518,000,000 | $4,930,000,000 |
| Receivables | $9,570,000,000 | $6,782,000,000 | $7,942,000,000 | $6,392,000,000 |
| Accounts Receivable | $9,570,000,000 | $6,782,000,000 | $7,268,000,000 | $5,563,000,000 |
| Cash Cash Equivalents And Short Term Investments | $9,129,000,000 | $11,973,000,000 | $10,944,000,000 | $9,305,000,000 |
| Cash And Cash Equivalents | $9,129,000,000 | $11,973,000,000 | $10,944,000,000 | $7,629,000,000 |
| Taxes Receivable | - | $198,000,000 | $172,000,000 | $129,000,000 |
| Debt | ||||
| Net Debt | $45,475,000,000 | $48,126,000,000 | $53,669,000,000 | $31,316,000,000 |
| Total Debt | $54,604,000,000 | $60,099,000,000 | $64,613,000,000 | $38,945,000,000 |
| Long Term Debt And Capital Lease Obligation | $50,005,000,000 | $56,549,000,000 | $63,170,000,000 | $37,354,000,000 |
| Long Term Debt | $50,005,000,000 | $56,549,000,000 | $63,170,000,000 | $37,354,000,000 |
| Current Debt And Capital Lease Obligation | $4,599,000,000 | $3,550,000,000 | $1,443,000,000 | $1,591,000,000 |
| Current Debt | $4,599,000,000 | $3,550,000,000 | $1,443,000,000 | $1,591,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $81,928,000,000 | $85,962,000,000 | $90,922,000,000 | $61,460,000,000 |
| Total Non Current Liabilities Net Minority Interest | $56,439,000,000 | $62,863,000,000 | $72,530,000,000 | $45,773,000,000 |
| Other Non Current Liabilities | $2,378,000,000 | $2,349,000,000 | $2,326,000,000 | $2,651,000,000 |
| Tradeand Other Payables Non Current | $2,690,000,000 | $2,349,000,000 | $4,680,000,000 | $5,757,000,000 |
| Non Current Deferred Liabilities | $1,366,000,000 | $1,616,000,000 | $2,354,000,000 | $11,000,000 |
| Non Current Deferred Taxes Liabilities | $1,366,000,000 | $1,616,000,000 | $2,354,000,000 | $11,000,000 |
| Current Liabilities | $25,489,000,000 | $23,099,000,000 | $18,392,000,000 | $15,687,000,000 |
| Payables And Accrued Expenses | $19,453,000,000 | $18,220,000,000 | $15,568,000,000 | $12,997,000,000 |
| Payables | $4,104,000,000 | $5,769,000,000 | $4,459,000,000 | $3,904,000,000 |
| Dividends Payable | $1,358,000,000 | $1,278,000,000 | $1,205,000,000 | $1,137,000,000 |
| Total Tax Payable | $379,000,000 | $2,583,000,000 | $1,664,000,000 | $1,195,000,000 |
| Income Tax Payable | $379,000,000 | $2,583,000,000 | $1,664,000,000 | $1,195,000,000 |
| Accounts Payable | $2,367,000,000 | $1,908,000,000 | $1,590,000,000 | $1,572,000,000 |
| Interest Payable | - | $867,000,000 | $936,000,000 | $470,000,000 |
| Equity | ||||
| Common Stock Equity | $8,658,000,000 | $5,877,000,000 | $6,232,000,000 | $3,661,000,000 |
| Total Equity Gross Minority Interest | $8,658,000,000 | $5,877,000,000 | $6,232,000,000 | $3,661,000,000 |
| Stockholders Equity | $8,658,000,000 | $5,877,000,000 | $6,232,000,000 | $3,661,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-258,000,000 | $-66,000,000 | $-289,000,000 | $-231,000,000 |
| Other Equity Adjustments | $-56,000,000 | $308,000,000 | $9,000,000 | $117,000,000 |
| Retained Earnings | $-25,107,000,000 | $-27,590,000,000 | $-26,549,000,000 | $-28,622,000,000 |
| Other | ||||
| Ordinary Shares Number | $538,800,000 | $537,000,000 | $535,400,000 | $534,000,000 |
| Share Issued | $538,800,000 | $537,000,000 | $535,400,000 | $534,000,000 |
| Tangible Book Value | $-32,298,000,000 | $-40,459,000,000 | $-45,038,000,000 | $-27,948,000,000 |
| Invested Capital | $63,262,000,000 | $65,976,000,000 | $70,845,000,000 | $42,606,000,000 |
| Working Capital | $3,568,000,000 | $5,931,000,000 | $11,940,000,000 | $6,499,000,000 |
| Total Capitalization | $58,663,000,000 | $62,426,000,000 | $69,402,000,000 | $41,015,000,000 |
| Foreign Currency Translation Adjustments | $-202,000,000 | $-374,000,000 | $-298,000,000 | $-348,000,000 |
| Capital Stock | $34,023,000,000 | $33,533,000,000 | $33,070,000,000 | $32,514,000,000 |
| Common Stock | $34,023,000,000 | $33,533,000,000 | $33,070,000,000 | $32,514,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,437,000,000 | $1,329,000,000 | $1,381,000,000 | $1,099,000,000 |
| Current Accrued Expenses | $15,349,000,000 | $12,451,000,000 | $11,109,000,000 | $9,093,000,000 |
| Goodwill | $18,680,000,000 | $18,637,000,000 | $18,629,000,000 | $15,529,000,000 |
| Net PPE | $7,913,000,000 | $6,543,000,000 | $5,941,000,000 | $5,427,000,000 |
| Accumulated Depreciation | $-11,120,000,000 | $-10,388,000,000 | $-9,808,000,000 | $-9,283,000,000 |
| Gross PPE | $19,033,000,000 | $16,931,000,000 | $15,749,000,000 | $14,710,000,000 |
| Construction In Progress | $3,390,000,000 | $2,053,000,000 | $1,550,000,000 | $1,213,000,000 |
| Other Properties | $5,220,000,000 | $4,996,000,000 | $4,813,000,000 | $4,684,000,000 |
| Machinery Furniture Equipment | $5,143,000,000 | $4,733,000,000 | $4,540,000,000 | $4,320,000,000 |
| Buildings And Improvements | $4,932,000,000 | $4,803,000,000 | $4,507,000,000 | $4,201,000,000 |
| Land And Improvements | $348,000,000 | $346,000,000 | $339,000,000 | $292,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,885,000,000 | $2,060,000,000 | $2,778,000,000 | $1,004,000,000 |
| Work In Process | $3,425,000,000 | $4,120,000,000 | $5,747,000,000 | $3,098,000,000 |
| Raw Materials | $915,000,000 | $818,000,000 | $993,000,000 | $828,000,000 |
| Duefrom Related Parties Current | - | $521,000,000 | $502,000,000 | $700,000,000 |
| Treasury Shares Number | - | - | $0 | - |
| Unrealized Gain Loss | - | - | $0 | $0 |
| Other Short Term Investments | - | - | $0 | $1,676,000,000 |
| Current Provisions | - | - | - | $548,000,000 |
Fetched: 2026-05-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $8,100,000,000 | $10,394,000,000 | $7,359,000,000 | $8,785,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $9,958,000,000 | $11,490,000,000 | $8,471,000,000 | $9,721,000,000 |
| Cash Flow From Continuing Operating Activities | $9,958,000,000 | $11,490,000,000 | $8,471,000,000 | $9,721,000,000 |
| Operating Gains Losses | $-2,064,000,000 | $159,000,000 | $-1,565,000,000 | $1,585,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,858,000,000 | $-1,096,000,000 | $-1,112,000,000 | $-936,000,000 |
| Investing Cash Flow | $-1,943,000,000 | $-1,046,000,000 | $-26,204,000,000 | $-6,044,000,000 |
| Cash Flow From Continuing Investing Activities | $-1,943,000,000 | $-1,046,000,000 | $-26,204,000,000 | $-6,044,000,000 |
| Net Other Investing Changes | $-32,000,000 | $50,000,000 | $224,000,000 | $100,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-200,000,000 | $0 | $-6,360,000,000 |
| Financing Cash Flow | $-10,859,000,000 | $-9,415,000,000 | $21,048,000,000 | $-4,037,000,000 |
| Cash Flow From Continuing Financing Activities | $-10,859,000,000 | $-9,415,000,000 | $21,048,000,000 | $-4,037,000,000 |
| Net Other Financing Charges | $-735,000,000 | $-783,000,000 | $-719,000,000 | $-400,000,000 |
| Cash Dividends Paid | $-5,124,000,000 | $-4,832,000,000 | $-4,556,000,000 | $-4,196,000,000 |
| Common Stock Dividend Paid | $-5,124,000,000 | $-4,832,000,000 | $-4,556,000,000 | $-4,196,000,000 |
| Net Common Stock Issuance | $0 | $-200,000,000 | $0 | $-6,360,000,000 |
| Other | ||||
| Repayment Of Debt | $-5,000,000,000 | $-3,600,000,000 | $-1,454,000,000 | $0 |
| Issuance Of Debt | $0 | $0 | $27,777,000,000 | $6,919,000,000 |
| End Cash Position | $9,129,000,000 | $11,973,000,000 | $10,944,000,000 | $7,629,000,000 |
| Beginning Cash Position | $11,973,000,000 | $10,944,000,000 | $7,629,000,000 | $7,989,000,000 |
| Changes In Cash | $-2,844,000,000 | $1,029,000,000 | $3,315,000,000 | $-360,000,000 |
| Common Stock Payments | $0 | $-200,000,000 | $0 | $-6,360,000,000 |
| Net Issuance Payments Of Debt | $-5,000,000,000 | $-3,600,000,000 | $26,323,000,000 | $6,919,000,000 |
| Net Long Term Debt Issuance | $-5,000,000,000 | $-3,600,000,000 | $26,323,000,000 | $6,919,000,000 |
| Long Term Debt Payments | $-5,000,000,000 | $-3,600,000,000 | $-1,454,000,000 | $0 |
| Long Term Debt Issuance | $0 | $0 | $27,777,000,000 | $6,919,000,000 |
| Net Investment Purchase And Sale | $0 | $0 | $1,673,000,000 | $-1,369,000,000 |
| Sale Of Investment | $0 | $0 | $1,673,000,000 | $1,218,000,000 |
| Net Business Purchase And Sale | $-53,000,000 | $0 | $-26,989,000,000 | $-3,839,000,000 |
| Purchase Of Business | $-53,000,000 | $0 | $-26,989,000,000 | $-3,839,000,000 |
| Net PPE Purchase And Sale | $-1,858,000,000 | $-1,096,000,000 | $-1,112,000,000 | $-936,000,000 |
| Purchase Of PPE | $-1,858,000,000 | $-1,096,000,000 | $-1,112,000,000 | $-936,000,000 |
| Change In Working Capital | $-1,978,000,000 | $2,365,000,000 | $-484,000,000 | $-733,000,000 |
| Change In Other Working Capital | $499,000,000 | $92,000,000 | $953,000,000 | - |
| Change In Other Current Liabilities | $-156,000,000 | $-51,000,000 | $-222,000,000 | $-182,000,000 |
| Change In Other Current Assets | $-1,267,000,000 | $-652,000,000 | $-564,000,000 | $258,000,000 |
| Change In Payables And Accrued Expense | $736,000,000 | $3,000,000 | $-127,000,000 | $679,000,000 |
| Change In Accrued Expense | $2,065,000,000 | $1,194,000,000 | $935,000,000 | $943,000,000 |
| Change In Payable | $-1,329,000,000 | $-1,191,000,000 | $-1,062,000,000 | $-264,000,000 |
| Change In Account Payable | $428,000,000 | $312,000,000 | $-402,000,000 | $154,000,000 |
| Change In Tax Payable | $-1,757,000,000 | $-1,503,000,000 | $-660,000,000 | $-418,000,000 |
| Change In Income Tax Payable | $-1,757,000,000 | $-1,503,000,000 | $-660,000,000 | $-418,000,000 |
| Change In Inventory | $886,000,000 | $2,532,000,000 | $491,000,000 | $-742,000,000 |
| Change In Receivables | $-2,676,000,000 | $441,000,000 | $-1,015,000,000 | $-746,000,000 |
| Changes In Account Receivables | $-2,676,000,000 | $441,000,000 | $-1,015,000,000 | $-746,000,000 |
| Other Non Cash Items | $149,000,000 | $-177,000,000 | $-277,000,000 | $-303,000,000 |
| Stock Based Compensation | $494,000,000 | $530,000,000 | $431,000,000 | $401,000,000 |
| Asset Impairment Charge | $1,200,000,000 | $159,000,000 | $851,000,000 | - |
| Deferred Tax | $-721,000,000 | $-1,228,000,000 | $-1,273,000,000 | $-1,198,000,000 |
| Deferred Income Tax | $-721,000,000 | $-1,228,000,000 | $-1,273,000,000 | $-1,198,000,000 |
| Depreciation Amortization Depletion | $5,167,000,000 | $5,592,000,000 | $4,071,000,000 | $3,417,000,000 |
| Depreciation And Amortization | $5,167,000,000 | $5,592,000,000 | $4,071,000,000 | $3,417,000,000 |
| Depreciation | $5,167,000,000 | $5,592,000,000 | $4,071,000,000 | $3,417,000,000 |
| Gain Loss On Investment Securities | $-2,064,000,000 | $159,000,000 | $-1,565,000,000 | $127,000,000 |
| Net Income From Continuing Operations | $7,711,000,000 | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 |
| Purchase Of Investment | - | $0 | $-1,000,000 | $-2,587,000,000 |
| Earnings Losses From Equity Investments | - | $-10,000,000 | $11,000,000 | $891,000,000 |
| Gain Loss On Sale Of Business | - | $0 | $0 | $567,000,000 |
| Sale Of Business | - | - | - | $130,000,000 |
Fetched: 2026-05-21